Celyad set to scale up China-focused R&D activities after linking with Medisun

Nick Paul Taylor

Cell therapy specialist is set to add Hong Kong to the clinical trial program of its ischemic heart failure treatment, giving its newly recruited partner data to support an attempt to crack the potentially lucrative Chinese market.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS